Mevion Unveils Innovative Proton Therapy System at ESTRO 2026

Mevion Medical Systems is set to transform cancer treatment in Europe with the introduction of the MEVION S250-FIT™ Proton Therapy System, showcased at ESTRO 2026. This advanced system is the first of its kind designed to fit into a standard radiation therapy vault, making it accessible for integration into existing LINAC-based treatment facilities across the region.

Certified by both the U.S. FDA and the European Union under Regulation 2017/745, the MEVION S250-FIT™ offers a feasible approach for European cancer centers to incorporate proton therapy without the need for extensive infrastructure modifications. This advancement aligns with the infrastructure, workflows, and financial planning common in contemporary radiation oncology.

In a pioneering installation, Stanford Medicine became the first institution globally to integrate the S250-FIT™ system in partnership with Leo Cancer Care. The setup was completed within an existing 110 square meter LINAC vault at their Cancer Center in Palo Alto, showcasing the system’s capability to operate within conventional clinical settings.

Tina Yu, CEO and President of Mevion Medical Systems, emphasized the system's breakthrough potential, stating, "For the first time, proton therapy can be deployed within the same clinical framework as conventional radiotherapy. This innovation allows European health systems to reconsider their strategy from investing in separate proton facilities to integrating this technology into their existing programs."

Incorporating Mevion’s HYPERSCAN® pencil beam scanning technology, the S250-FIT system supports advanced techniques such as DirectARC™ proton arc therapy. It is designed for adaptive workflows and is FLASH research-ready. The system also includes the Marie® Upright Patient Positioning and CT Imaging System from Leo Cancer Care, which is the first commercial platform offering an upright treatment position integrated with a diagnostic CT. This configuration benefits patient comfort and aids in managing organ motion during treatment.

The technology builds on the MEVION S250i®’s core, which is operational in both the U.S. and the Netherlands, offering Mevion substantial clinical experience with single-room proton therapy setups. Mevion's global partnerships for S250-FIT include Stanford Health Care and other prominent institutions such as Loma Linda University Health and UNC Health.